Inclusion Criteria:

• Histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal serous cancer, papillary serous endometrial cancer, or fallopian tube cancer
• Must have responded and remained clinically stable (as defined by normal clinical examination, normal serum CA125 level and normal CT scan) after first-line platinum-based regimen followed by bevacizumab maintenance therapy
• Must have developed relapsed disease at least 3 months after completion of bevacizumab maintenance therapy as defined by a) development of new, measurable lesions by RECIST criteria, but no lesion with maximum diameter greater than 3 centimeters OR b) newly elevated CA125 level at least 2 x ULN on 2 separate occasions, obtained at least 1 day but not more than 3 months apart
• ECOG Performance Status 0-2
• No prior cytotoxic chemotherapy or biologic therapy for disease recurrence allowed
• Prior hormonal-based therapy for ovarian, primary peritoneal serous or fallopian tube cancer is allowed
• Toxic side effects related to prior chemotherapy or hormonal therapy must have resolved to grade one or less or to baseline before initiation of bevacizumab
• 18 years of age or older
• Life expectancy of 6 months or greater
• Normal organ and marrow function as outlined in the protocol

Exclusion Criteria:

• Prior cytotoxic chemotherapy or biologic therapy for disease recurrence
• Known CNS disease, except for treated brain metastasis
• Pregnancy or breast feeding
• Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipation of need for major surgical procedure during the course of the study
• Core biopsy or other minor surgical procedure, excluding placement of a vascular device, within 7 days prior to enrollment
• History of abdominal fistula, GI perforation, intra-abdominal abscess, or CT evidence of bowel obstruction or bowel wall thickening
• Symptoms of intestinal obstruction, or requirement of parenteral hydration and/or nutrition
• History of active malignancy during the last 3 years, except non-melanomatous skin cancer or in situ breast or cervical cancer
• Evidence of preexisting uncontrolled hypertension. If patient has hypertension, it must be medically controlled (< 150/90) prior to starting bevacizumab
• Proteinuria at screening
• Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent
• Therapeutic anticoagulation is not by itself and exclusion criterion. However, for certain high risk patients on therapeutic anticoagulation, eligibility will be determined after discussion with the overall PI
• Any active bleeding
• Serious, non-healing wound, ulcer, or bone fracture
• Prior history of hypertensive crisis or hypertensive encephalopathy
• NYHA Grade II or greater congestive heart failure
• History of myocardial infarction or unstable angina within 6 months prior to Day 1
• History of stroke or transient ischemic attack within 6 months prior to day 1
• Significant vascular disease within 6 months prior to day 1
• History of hemoptysis within 1 month prior to day 1
• Presence of measurable lesion(s) by RECIST criteria with maximum diameter greater than 3 centimeters